STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide.
The last earnings update was 36 days ago.
Discounted Cash Flow Calculation for MUN:SAZ using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
MUN:SAZ DCF 1st Stage: Next 10 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
STADA Arzneimittel's earnings available for a low price, and how does
this compare to other companies in the same industry?
STADA Arzneimittel's earnings are expected to grow by 7.3% yearly, however this is not considered high growth (20% yearly).
Unable to determine if STADA Arzneimittel is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
STADA Arzneimittel's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
5/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
STADA Arzneimittel's finances.
The net worth of a company is the difference between its assets and liabilities.
STADA Arzneimittel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
STADA Arzneimittel's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
STADA Arzneimittel's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Peter Goldschmidt serves as the President of Sandoz Inc. Mr. Goldschmidt serves as Head of North American Operations at Sandoz International GmbH and has been its President of Sandoz US since July 2013. Mr. Goldschmidt serves as Chairman of the Executive Board and Chief Executive Officer at STADA Arzneimittel Aktiengesellschaft since September 1, 2018. Mr. Goldschmidt served as Head of Commercial Operations for North America at Sandoz International GmbH. Mr. Goldschmidt served as the Head of Central and Eastern Europe at Sandoz International GmbH and Novartis AG (Formerly Sandoz AG) since January 2009. Mr. Goldschmidt joined Sandoz from Novartis where he served as Country Group Head for the Philippines, Singapore and Indonesia. He joined Novartis Group in 1990 and held a number of positions in marketing, sales, strategic planning and organizational development. Mr. Goldschmidt served as Country President for Novartis Healthcare in the Philippines since July 2007. Mr. Goldschmidt served as Head of Marketing Sales of Novartis Germany from 2001 to 2007. He served as Head of Marketing for Novartis in Sweden from 1999 to 2001. Mr. Goldschmidt served as Chairman of Supervisory Board at Lek Pharmaceuticals d.d. since June 2009. He serves as Director of Association for Accessible Medicines. He served as a Member of the Supervisory Board at GfK SE since December 2, 2016 until April 13, 2017. Mr. Goldschmidt is a graduate in Politics and Economic Geography at the University of Muenster in Germany and holds a Masters degree in Sociology. He has completed Post-graduate studies at the London Business School, UK, the Harvard Business School and Stanford Business School in the US.
Insufficient data for Peter to compare compensation growth.
Peter's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the STADA Arzneimittel management team is less than 2 years, this suggests a new team.
Chairman of the Executive Board & CEO
CFO & Member of Executive Board
CTO & Member of Executive Board
Executive Vice President of Corporate Communication
Director of Investor Relations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the STADA Arzneimittel board of directors is less than 3 years, this suggests a new board.
Can STADA Arzneimittel Aktiengesellschaft's (MUN:SAZ) ROE Continue To Surpass The Industry Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows STADA Arzneimittel has a return on equity of 19% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux. The Branded Products segment offers APO-Go for Parkinson’s disease; Grippostad for cold; Aqualor for rhinitis/soare throat; Snup for rhinitis; and Vitaprost for prostate disease. It serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.